Efficacy of Intracavernosal Xeomin With Tadalafil for Mild-Moderate Erectile Dysfunction

Inclusion Criteria: * Written informed consent obtained from the subject * History of ED for at least 6 months prior to screening, defined as "the inability to achieve and maintain an erection of the penis sufficient to complete satisfactory sexual intercourse" (NIH), the diagnosis of ED has to be confirmed by a physician * Understanding of study procedures and willingness to abide by all procedures during the course of the study * Male subject aged ≥18 to ≤ 80 years at visit 1 * Have a monogamous relationship with a female sexual partner (vaginal penetration required for several of the primary efficacy variables) for at least 6 months prior to screening * Highly motivated to obtain treatment for ED * History of previous use of at least 1 marketed PDE5 inhibitor and insufficient therapeutic efficacy despite use of the highest approved dose Exclusion Criteria: * Hypersensitivity to the active substance (Clostridium Botulinum neurotoxin type A) or to any of the excipients (Human albumin, sucrose) * BW \<50 kg * Diagnosis of spinal cord injury * ED caused by other primary sexual disorders including premature ejaculation or ED caused by untreated endocrine disease (e.g., hypopituitarism, hypothyroidism, or hypogonadism) * History of penile implant. * The presence of clinically significant penile deformity in the opinion of the investigator. * Concomitant diagnosis of Peyronie's disease * Patients with chronic stable angina treated with long-acting nitrates, or patients with ch…